Treatment
- abiraterone
- anastrozole
- bicalutamide
- capecitabine
- CAPOX
- carboplatin
- cetuximab
- cisplatin
- crizotinib
- dacarbazine
- docetaxel
- doxorubicin
- epirubicin
- erlotinib
- everolimus
- exemestane
- fluorouracil
- flutamide
- FOLFOX
- FOLFIRI
- fulvestrant
- gefitinib
- gemcitabine
- goserelin
- imatinib
- irinotecan
- lapatinib
- letrozole
- leuprolide
- liposomal doxorubicin
- megestrol acetate
- nab-paclitaxel
- oxaliplatin
- paclitaxel
- panitumumab
- pemetrexed
- pertuzumab
- sorafenib
- sunitinib
- tamoxifen
- temozolomide
- temsirolimus
- topotecan
- toremifene
- trastuzumab
- vemurafenib
paclitaxel
Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from
tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability
results in the inhibition of the normal dynamic reorganization of the microtubule network
that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays, or "bundles," of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis. Paclitaxel is indicated* for treatment of ovarian cancer, breast cancer, small cell lung
cancer and Kaposi's sarcoma.
*Please refer to full prescribing information/package insert for precise indications.
